Iovance Biotherapeutics (NASDAQ:IOVA) Upgraded by Citizens Jmp to “Market Outperform” Rating

Iovance Biotherapeutics (NASDAQ:IOVA) was upgraded by stock analysts at Citizens Jmp from a “market perform” rating to a “market outperform” rating in a research report issued to clients and investors on Wednesday, Marketbeat reports. The brokerage presently has a $5.00 price objective on the biotechnology company’s stock. Citizens Jmp’s price objective would suggest a potential upside of 32.28% from the company’s current price.

IOVA has been the subject of a number of other reports. Barclays upped their price objective on Iovance Biotherapeutics from $9.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. The Goldman Sachs Group reiterated a “sell” rating and set a $2.00 target price on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. HC Wainwright reduced their price target on shares of Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, October 29th. Finally, Chardan Capital decreased their price target on shares of Iovance Biotherapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $10.00.

Iovance Biotherapeutics Price Performance

Shares of NASDAQ IOVA opened at $3.78 on Wednesday. The company has a 50-day simple moving average of $2.64 and a 200-day simple moving average of $2.40. The company has a market cap of $1.50 billion, a PE ratio of -3.15 and a beta of 0.76. Iovance Biotherapeutics has a 12 month low of $1.64 and a 12 month high of $5.64.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. The firm had revenue of $86.77 million for the quarter, compared to analyst estimates of $81.61 million. Iovance Biotherapeutics had a negative net margin of 158.78% and a negative return on equity of 55.24%. On average, analysts anticipate that Iovance Biotherapeutics will post -1.24 EPS for the current year.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of institutional investors have recently modified their holdings of the stock. Invesco Ltd. grew its stake in Iovance Biotherapeutics by 32.4% in the fourth quarter. Invesco Ltd. now owns 1,251,665 shares of the biotechnology company’s stock worth $3,417,000 after purchasing an additional 306,195 shares in the last quarter. XTX Topco Ltd increased its holdings in shares of Iovance Biotherapeutics by 148.4% in the 4th quarter. XTX Topco Ltd now owns 522,934 shares of the biotechnology company’s stock valued at $1,428,000 after acquiring an additional 312,413 shares during the last quarter. VARCOV Co. acquired a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at approximately $253,000. Virtus Investment Advisers LLC lifted its stake in Iovance Biotherapeutics by 61.5% during the fourth quarter. Virtus Investment Advisers LLC now owns 310,641 shares of the biotechnology company’s stock worth $848,000 after purchasing an additional 118,263 shares during the last quarter. Finally, Tudor Investment Corp ET AL boosted its holdings in Iovance Biotherapeutics by 47.4% in the fourth quarter. Tudor Investment Corp ET AL now owns 179,494 shares of the biotechnology company’s stock worth $490,000 after purchasing an additional 57,750 shares during the period. Institutional investors and hedge funds own 77.03% of the company’s stock.

Key Headlines Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: FDA approved lifileucel (Amtagvi) for metastatic melanoma, shifting the program from a pipeline bet to a commercialization and execution test; company cites favorable real‑world response/safety data and Fast Track status in 2L non‑small cell lung cancer — larger label/indication opportunities and regulatory momentum support adoption and revenue upside. Iovance FDA Approval Shifts Lifileucel From Pipeline Bet To Execution Test
• Positive Sentiment: Positive pilot TIL trial results in advanced soft‑tissue sarcomas (50% objective response rate reported) from an MSKCC‑led study — expands Amtagvi’s addressable indications and appears to be the immediate catalyst behind heavy buying and the stock jump. Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
• Positive Sentiment: Q4 2025 results beat: revenue ~$86.8M (above estimates), EPS loss narrower than expected and management cites ~30% revenue growth and improving gross margins — supports the thesis that commercialization of Amtagvi is ramping and moves the company closer to profitability. Iovance outlines surge toward profitability with 30% revenue growth in Q4 2025
• Neutral Sentiment: Analyst coverage and bullish notes are arriving (some price targets and a higher “floor” rating) reflecting better margins and faster turnaround assumptions, but firms still flag high risk — sentiment lift but tempered by execution risk. Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)
• Neutral Sentiment: Unusual options activity — heavy call buying (large increase vs. normal volume) indicates speculative positioning that can amplify intraday moves in either direction. (No direct article link — reported market activity.)
• Negative Sentiment: Company remains unprofitable with a deeply negative net margin and negative ROE; analysts note cash runway into mid‑2027 and material dilution risk since Amtagvi is not expected to be cash‑positive immediately — execution, manufacturing scale and potential fundraising are key downside risks. Iovance stock profile and Q4 metrics
• Negative Sentiment: Operational challenges remain — manufacturing scale, wider adoption outside specialized centers and the need for expanded registrational trials could delay revenue visibility and increase costs, keeping upside conditional on successful execution. Iovance FDA Approval Shifts Lifileucel From Pipeline Bet To Execution Test

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.